在EGFR突变高级NSCLC中治疗序列
M Wespiser1, A Swalduz1, M Pérol1
1Department of Medical Oncology, Centre Léon Bérard, 28 rue Laënnec, 69008 Lyon, France.
Lung cancer (Amsterdam, Netherlands)
|July 24, 2024
概括
EGFR突变导致非小细胞肺癌 (NSCLC). 虽然EGFR氨酸激酶抑制剂 (TKIs) 提高了生存率,但耐药性发展,需要针对晚期NSCLC患者制定新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 常见的表皮生长因子受体 (EGFR) 基因突变,包括19号外因子删除和21号外因子中的L858R,是非小细胞肺癌 (NSCLC) 中的主要可操作的基因组改变.
- 第三代EGFR氨酸激酶抑制剂 (TKI) 代表了先进NSCLC第一线治疗的新标准,显著改变了疾病进展和生存率.
研究的目的:
- 对具有常见EGFR突变的晚期NSCLC的现有和新兴治疗策略进行审查.
- 讨论克服抵抗机制和管理残留疾病的方法.
- 为临床医生提出一个管理算法,整合临床和生物参数.
主要方法:
- 审查已发表和即将推出的NSCLC治疗方面的进展.
- 针对EGFR突变和耐药性途径的治疗策略的分析.
- 开发一个临床决策算法.
主要成果:
- EGFR TKIs改善了生存率,但耐药性和异质性限制了长期的结果.
- 组合疗法对无进展的生存有希望,但可能会增加副作用.
- 对于具有EGFR突变的晚期NSCLC,正在出现不同的治疗序列.
结论:
- 新的治疗选择有可能改善EGFR突变的晚期NSCLC的治疗结果.
- 需要进一步了解对生存和生活质量的影响.
- 考虑临床和生物因素的个性化管理方法至关重要.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.1K
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.8K
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
